By Colin Kellaher
The top executive of Medtronic's cardiovascular portfolio, Sean Salmon, is leaving the medical-technology company.
Medtronic on Wednesday said Skip Kiil, previously senior vice president and president of its cranial and spinal-technologies business, has replaced Salmon as executive vice president and president of the cardiovascular portfolio, which accounted for roughly 37% of the company's $33.5 billion in revenue for its latest fiscal year.
Medtronic said Salmon, who joined the company in 2004 and has been at the helm of the cardiovascular portfolio since the start of 2021, is entitled to severance payments and benefits and will remain an employee until Sept. 2.
The company said Michael Carter, vice president and general manager of its spine business, succeeds Kiil as senior vice president and president of the cranial and spinal-technologies business.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 21, 2025 07:23 ET (11:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。